Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia by Ye, Dongjiu et al.
ORIGINAL ARTICLE
Analysis of Aurora kinase A expression in CD34
+ blast cells
isolated from patients with myelodysplastic syndromes
and acute myeloid leukemia
Dongjiu Ye & Guillermo Garcia-Manero &
Hagop M. Kantarjian & Lianchun Xiao &
Saroj Vadhan-Raj & Michael H. Fernandez &
Martin H. Nguyen & L. Jeffrey Medeiros &
Carlos E. Bueso-Ramos
Received: 10 June 2008 /Accepted: 30 August 2008 / Published online: 4 November 2008
# Springer-Verlag 2008
Abstract Aurora kinase A, also known as aurora A, is a
serine/threonine kinase that plays critical roles in mitosis
entry, chromosome alignment, segregation, and cytokinesis.
Overexpression of aurora A has been observed in many
solid tumors and some hematopoietic neoplasms, but little
is known about its expression in myeloid diseases. Because
cytogenetic abnormalities play an essential role in the
pathogenesis of myeloid malignancies, we hypothesized
that aurora A deregulation may be involved in myelodys-
plastic syndromes and acute myeloid leukemia and con-
tribute to the chromosomal instability observed in these
diseases. We assessed aurora A mRNA levels in CD34
+
bone marrow blasts from nine patients with acute myeloid
leukemia, 20 patients with myelodysplastic syndromes, and
five normal patients serving as controls. CD34
+ blasts were
isolated from bone marrow aspirate specimens using
magnetic activated cell separation technology. RNA was
extracted from purified CD34
+ cells, and quantitative real-
time reverse transcriptase polymerase chain reaction for
aurora Awas performed. Immunocytochemical analyses for
total aurora A, phosphorylated aurora A, Ki-67, and
activated caspase 3 were performed on cytospin slides
made from purified CD34
+ cells in myelodysplastic
syndrome patients using standard methods. Aurora A
mRNA and protein levels were correlated, as was aurora
A mRNA level, with blast counts, cytogenetic abnormali-
ties, and International Prognostic Scoring System score. We
found that CD34
+ cells in myelodysplastic syndromes and
acute myeloid leukemia expressed aurora A at significantly
higher levels (P=0.01 and P=0.01, respectively) than
normal CD34
+ cells. Aurora A mRNA levels correlated
with total and phosphorylated protein levels (P=0.0002 and
P=0.02, respectively). No significant correlation was found
between aurora A mRNA level and blast count, blast
viability, cytogenetic abnormalities, or the International
Prognostic Scoring System score in patients with myelo-
dysplastic syndromes. We conclude that aurora A is up-
regulated in CD34
+ blasts from myeloid neoplasms.
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Introduction
Aurora kinases are a family of serine/threonine kinases that
includes three members designated as aurora A, B, and C
[1–3]. Aurora A (AA) is localized at the centrosome during
interphase, translocated to mitotic spindles in the early
mitotic phase, and degraded after the metaphase–anaphase
transition. Activation of AA is required for mitotic entry,
centrosome maturation, centrosome separation, and chro-
mosome alignment [1–3]. Aurora B localizes to the inner
centromere during prometaphase and metaphase and then to
the spindle midzone microtubules in late anaphase/telo-
phase and in the midbody during cytokinesis. Its main role
is to insure normal chromosomal alignment and cytokinesis
[1–3]. Aurora C is associated with aurora B in regulating
mitotic chromosome dynamics in mammalian cells [4].
Aurora A overexpression has been observed in several
solid tumors, including colon, breast, prostate, and gastric
cancers [5–8]. The expression level of AA correlated with
clinical stage in patients with prostate cancer [9]. Informa-
tion regarding the expression of aurora kinase expression in
hematologic neoplasia is limited. A group from Japan
studied aurora A and B expression in leukemia cell lines
and mononuclear cells isolated from leukemia patients and
found aberrant expression of aurora kinases in numerous
hematological malignancies, including acute myeloid leu-
kemia (AML), acute lymphoblastic leukemia, and chronic
myeloid leukemia [10, 11]. Furthermore, aberrant expres-
sion accompanied by high proliferation of neoplastic cells
was inhibited by selective aurora kinase inhibitors, suggest-
ing that aurora kinases play important roles in the growth
and proliferation of hematologic neoplasms [10, 11]. These
studies were substantiated by data published recently by a
Chinese group [12].
Myelodysplastic syndromes (MDS) are a heterogeneous
group of myeloid malignancies that are thought to be
hematological stem cell disorders. Myelodysplastic syn-
dromes are characterized by inefficient hematopoiesis, and
patients present clinically with cytopenia in one or more
lineages. Bone marrow aspiration and biopsy show hyper-
cellular but dysplastic hematopoiesis [13]. Although ap-
proximately half of MDS patients have cytogenetic
abnormalities, the pathogenesis of MDS and the roles of
the genetic abnormalities in tumorigenesis remain to be
defined. To our knowledge, the expression of aurora
kinases in MDS has not been assessed.
The goal of the current study was to investigate the level
of aurora A expression in MDS and AML and to correlate
the results with clinicopathologic and cytogenetic features.
Materials and methods
Patients and specimen sources
With informed consent from patients and approval from the
institutional review board of The University of Texas M. D.
Anderson Cancer Center, we obtained peripheral blood,
bone marrow aspirate, aspirate clot, and trephine biopsy
specimens from a total of 34 patients, including nine with
AML, 20 with MDS, and five with no evidence of
hematologic neoplasia used as reference controls. The
patient characteristics are shown in Table 1. The control
specimens were obtained from one patient with colon
cancer without bone marrow involvement and four patients
with anemia in whom the possibility of MDS was excluded.
The diagnoses of AML and MDS were reviewed and
confirmed by hematopathologists at M. D. Anderson
Cancer Center according to World Health Organization
criteria [13]. All cases were newly diagnosed and had not
undergone any treatment; these cases were chosen random-
ly from patients evaluated by the Department of Hema-
topathology at M. D. Anderson Cancer Center during 2007.
CD34
+ mononuclear cell enrichment
Bone marrow mononuclear cells were isolated from
anticoagulated bone marrow aspirate specimens by densi-
ty gradient centrifugation using a commercially available
system according to the manufacturer’s specifications
(Miltenyi Biotec, Auburn, CA, USA). A CD34
+ cell
isolation kit that contained isolation buffer [phosphate-
buffered saline (PBS) pH 7.2, 0.5% bovine serum
albumin, and 2 mM ethylene diamine tetraacetic acid], a
magnetic activated cell separation (MACS) column and
separator, and a PhycoErythrin-conjugated CD34 antibody
was used for the cell separation. CD34
+ cells were labeled
with magnetic microbeads, retained in the MACS column
while passing through a magnetic field, and eluted with
elution buffer after removal from the magnetic field. A
small sample of purified CD34
+ blasts were diluted with
PBS and assessed using an automatic cell counter to detect
the cell number and viability (Vi-Cell, Beckman Coulter,
Fullerton, CA, USA). A portion of the eluate was used to
make cytospin slides; the remainder was subjected to
centrifugation at 300×g f o r1 0m i na n dt h es u p e r n a t a n t
discarded.
Real-time reverse transcriptase polymerase chain reaction
Total RNA was extracted from CD34
+ mononuclear cells
using the standard Trizol method (Invitrogen, Carlsbad,
CA, USA). cDNA was prepared with the Quantitect RT Kit
(Qiagen, Valencia, CA, USA) according to the manufac-
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Taqman Universal PCR Mastermix (Applied Biosystems,
Foster City, CA, USA) and the aurora A assay kit on
demand (catalog number Hs01597773_mH, Applied Bio-
systems). Human β-actin mRNA was used as an internal
control, assayed using Taqman Universal PCR Mastermix
with concentrations of forward primer (CCCTGGCACC
CAGCAC) and reverse primer (GCCGATCCACACG
GAGTAC) of 400 nM each and probe (fam-ATCAAGAT
CATTGCTCCTCCTGAGCGC-bhq) of 100 nM. Real-time
reverse transcriptase polymerase chain reaction (RT-PCR)
was performed in an automatic MX3000P real-time PCR
thermal cycler (Stratagene, La Jolla, CA, USA). The
relative gene expression levels were normalized by β-actin
signal to eliminate the differences in total RNA amount and
reverse transcription efficiency. Relative RNA level was
reported via standard delta delta Ct (δδ Ct). cDNA purified
from normal CD34
+ hematopoietic progenitor cells was
used as calibrator sample (Allcells, LLC, Emeryville, CA,
USA).
Table 1 Clinical characteristics and test results of patients
No. Age
(years)
Sex Diagnosis BM Blast % Cytogenetics IPSS score ddCt AA
mRNA
1 65 M Colon cancer staging 0 NA NA 0.17
2 38 F Renal carcinoma history, R/O MDS 4 46, XX NA 0.41
3 57 F Anemia, R/O MDS 3 46, XX NA 0.20
4 86 M Anemia, R/O MDS 1 46, XY NA 0.55
5 65 M Anemia, R/O MDS 3 46, XY NA 0.36
6 70 M AML, NOS (WHO); AMML, M4 (FAB) 31 complex NA 0.71
7 41 M AML, NOS (WHO); AML, M6a (FAB) 22 complex NA 0.19
8 82 M AML, NOS (WHO) 33 complex NA 1.05
9 76 M AML, NOS (WHO); AML, M0 (FAB) 92 47, XY, + 13 NA 1.72
10 43 M AML with inv (16) (WHO);
AML, M4Eo (FAB)
30 46, XY, t(16;16)
(p13.1;q22)
NA 2.31
11 75 M AML arising from MDS (WHO);
M6a (FAB)
27 complex NA 0.99
12 71 M AML arising from MDS (WHO);
M4 (FAB)
75 46, XY, add (4) (P16), -7 NA 0.96
13 68 M AML with multilineage dysplasia 21 46, XY, inv (7) (q22q34) NA 0.87
14 59 F AML, therapy related (WHO) 23 complex NA 1.00
15 68 M RCMD (WHO) 2 46, XY 0 1.1
16 62 M RCMD (WHO) 0 46, XY 0.5 0.81
17 48 F RCMD (WHO) 1 46, XX 0 0.67
18 67 M RCMD (WHO) 3 NA NA 0.91
19 63 M RCMD (WHO) 4 complex 1 1.11
20 83 M RCMD (WHO) 2 46, XY 0 0.20
21 72 M RCMD RS (WHO) 2 47, XY, + 19 1 1.26
22 65 M RCMD RS (WHO) 3 46, XY 0 0.33
23 34 F MDS, therapy related (WHO) 5 2 0.61
24 68 M MDS, therapy related (WHO) 2 complex 1.5 1.08
25 40 M MDS, therapy related (WHO) 8 complex 2 0.39
26 79 M RAEB1 (WHO) 5 46, XY 1 0.76
27 71 M RAEB1 (WHO) 8 46, XY 0 0.51
28 64 M RAEB2 (WHO) 18 complex 2.5 0.39
29 67 M RAEB2 (WHO) 13 46, XY 1.5 0.62
30 77 M RAEB2 (WHO) 12 45, XY, -Y 1.5 0.44
31 77 M CMML-1(WHO) 8 46, XY 0.5 0.48
32 70 M CMML-2 (WHO) 12 45, X, -Y 2 0.98
33 76 M CMML-2 (WHO) 18 46, XY, I (17) (q10) 2.5 2.17
34 72 M MDS/MPD, NOS (WHO) 8 46, XY 1 0.84
IPSS International Prognostic Scoring System; ddCt AA aurora kinase A gene expression fold change compared to a reference sample, which was
read as 1; NA not applicable; MDS myelodysplastic syndromes; AML acute myeloid leukemia; NOS not otherwise specified; WHO World Health
Organization; AMML acute myelomonocytic leukemia; FAB French-American-British system; RCMD refractory cytopenia with multilineage
dysplasia; RS ringed sideroblasts; RAEB refractory anemia with excess blasts; MPD myeloproliferative disease; R/O rule out; CMML chronic
myelomonocytic leukemia
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Immunocytochemical analysis was performed using a
cytospin preparation of CD34
+ -enriched mononuclear cells
according to standard procedures. Antibodies specific for
the following proteins were tested: total AA and phosphor-
ylated (at threonine 288, active form) AA (pAA; Abcam,
Cambridge, MA, USA), CD34 (Biocare Medical, Concord,
CA, USA), and Ki-67 plus caspase 3 prediluted double
stain antibody (Biocare Medical). Expression of AA and
pAA was arbitrarily classified as low level if less than 50%
of blasts were positive and as high level if 50% or more
blasts were positive.
Cytogenetics and international prognostic scoring system
score
Standard conventional cytogenetics with G-band karyo-
typing was performed at our institution using bone
marrow aspirate specimens as described previously [14].
Fluorescence in situ hybridization was performed if
clinically indicated for the diagnoses of AML and MDS.
Patients with MDS were assigned an International Prog-
nosis Scoring System (IPSS) score, which is used
clinically to predict prognosis in MDS [15]. This score
integrates the bone marrow aspirate blast count, cytoge-
netic risk factors, and severity of cytopenias into a score
and classifies patients as low risk (score 0), intermediate
risk (0.5–2 ) ,o rh i g hr i s k( ≥2.5). The IPSS scores are
shown in Table 1.
Statistics
To compare the expression level of AA in different groups
(AML versus MDS versus control), the Kruskal–Wallis
rank sum test was used. To correlate AA mRNA levels with
immunocytochemical staining, the Spearman correlation
coefficient was computed. For correlations between AA
mRNA and blast count, complexity of cytogenetics, or
IPSS score, the Spearman correlation coefficient method
was used.
Results
AA mRNA expression levels in AML and MDS
Use of RT-PCR revealed that, in five control patients, AA
mRNA levels ranged from 0.17 to 0.55. In MDS patients,
the median AA mRNA level was 0.99 (range, 0.2 to 2.17).
In AML patients, the median AA mRNA level was 0.76
(range, 0.19 to 2.31). Compared with controls, AA mRNA
levels were significantly higher in both AML (P=0.01) and
MDS patients (P=0.01; Fig. 1). There was no significant
difference in AA mRNA levels between AML and MDS
patients.
Immunocytochemical stains
To validate that the purified mononuclear cells had
numerous blasts, anti-CD34 antibody was used for immu-
nostaining. Figure 2a, b shows that most (∼80%) of the
mononuclear cells isolated from control (Fig. 2a) or MDS
patients (Fig. 2b) were blasts immunoreactive with CD34.
Immunostains for total AA showed weak to no staining
in normal control specimens (Fig. 2c) and stronger
cytoplasmic staining in MDS patient specimens (Fig. 2d).
Similarly, immunostains for pAA showed weak to no stain
in normal controls (Fig. 2e) and stronger cytoplasmic
staining in MDS cases (Fig. 2f). Ki-67 stain highlighted a
small proportion of proliferative CD34
+ cells in both
normal control and MDS cases, and no statistically
significant difference existed between the two groups (dark
brown nuclear stain, Fig. 2g). Active caspase 3 stained the
cells undergoing apoptosis red. Only a small number of
cells stained red, and no statistically significant difference
existed between the control and MDS groups (Fig. 2h).
Correlation of AA mRNA and protein in MDS
AA mRNA levels correlated with total AA protein levels,
as assessed by immunocytochemical staining in MDS
patients (r=0.78, P=0.002; Fig. 3). Furthermore, AA
mRNA levels correlated with active phosphorylated AA
protein levels, as assessed by immunocytochemical staining
in MDS patients (P=0.02; not shown).
Conventional cytogenetic results in MDS patients
Table 1 shows the demographics and clinical characteristics
of all subjects. Table 2 shows the detailed cytogenetic
changes in MDS patients. Among the 20 MDS patients,
half had a normal karyotype, and the others showed various
abnormalities, including five patients with complex karyo-
types (three or more abnormalities). Two patients had
abnormalities involving chromosome 20, where the gene
for AA is located (20q13.2), one with monosomy 20 and
the other with del(20)(q11.2q13.3).
Correlation of AA mRNA with blast counts and viability,
cytogenetic risk factors, and IPSS score
No significant correlation was found in MDS patients
between AA mRNA levels and bone marrow blast counts
(P=0.50), blast cell viability (P=0.38), cytogenetic risk
factors (P=0.45), or IPSS score (P=0.51) (Table 3).
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Our study showed deregulated aurora A expression in CD34
+
blasts cells isolated from patients with untreated myelodys-
plastic syndromes and acute myeloid leukemia. We found that
AA mRNA was expressed at significantly higher levels in
both AML and MDS patients than in controls. Furthermore,
AA mRNA expression correlated strongly with both total AA
and phosphorylated (active) AA protein, as assessed by
immunocytochemical staining of CD34
+ cells. Although
AA protein is known to localize in centrosomes and mitotic
spindles at the G2 to M phase transition, immunocytochem-
ical staining has shown that most cells are positive for AA in
a diffuse, cytoplasmic pattern, regardless of their cell cycle
status [8, 16, 17]. The current study revealed dual cytoplas-
mic and nuclear staining for AA in AML and MDS, but the
staining patterns were different: the cytoplasmic staining was
diffuse, whereas the nuclear staining had a punctate pattern.
To our knowledge, no previous study has investigated AA
expression in MDS or has correlated nuclear or cytoplasmic
staining with mRNA levels.
Our results showed good correlation between AA
mRNA and cytoplasmic AA protein levels, further strength-
ened by the strong correlation found between the AA
Fig. 1 AA mRNA levels in
both AML and MDS patients
Fig. 2 Immunocytochemical stains. Mononuclear CD34
+ cells isolat-
ed from control (a) or MDS patients (b); total AA in normal control
specimens (c) and in MDS patient specimens (d); pAA in normal
controls (e) and in MDS cases (f); proliferative Ki-67
+ cells (g) and
apoptotic active caspase 3
+ cells (h) in MDS cases
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findings are consistent with those in a recently published
study showing high-level expression of AA in CD34
+
blasts in AML patients [12].
Our results did not show a significant correlation of
AA mRNA with bone marrow blast counts, viability of
CD34
+ blast cells, cytogenetic abnormalities, IPSS score,
proliferation index assessed by Ki-67 stain, or apoptotic
activity assessed by active caspase 3 staining. Several
hypotheses may explain these findings. First, AA may be
important in the initiation of MDS but not in its
progression. If AA plays an important role in early-stage
MDS and its level remains high in later stages, this level
may remain high regardless of disease severity, a theory
supported by our results. The exact mechanism for the
pathogenesis of MDS is not known, but a “multifactorial
and multistep” theory is well accepted [18], which states
that genetic damage or instability occurs early in the
development of the disease. The genetic damage could be
hereditary, as in pediatric MDS, or acquired from
irradiation, chemotherapy, immunomodulation, or inflam-
mation. The fact that most adult MDS patients are elderly
(mean age close to 70 years) suggests that environmental
factors play an important role.
Second, MDS is a heterogeneous combination of
syndromes with various pathogenic pathways. Our limited
number of study subjects with various subtypes of MDS
may have made identification of correlations more difficult.
Third, AA levels may be associated with genetic changes in
MDS, although our current studies did not detect this
association. Conventional cytogenetic analysis is very
useful for studying genomic changes but is neither specific
Fig. 3 AA mRNA levels
correlated with total AA protein
levels
Table 2 Detailed cytogenetic profiles in MDS patients
No. Diagnosis Cytogenetics
1 RCMD (WHO) 46, XY
2 RCMD (WHO) 46, XY
3 t-MDS (WHO) 45, XY, 6q-, -7, 12p-
4 RCMD (WHO) 46, XY
5 t-MDS (WHO) 45,XY,del(5)(q22q35),dic(6;21)
(p25;p11.2)[18] 45,XY,del(5)
(q22q35),del(6)(q13q25),del(7)
(q22q34),-20[2]
6 RCMD (WHO) NA
7 RCMD (WHO) 46,XY,del(5)(q22q35),del(11)(q23)[6]
46,XY,del(5)(q22q35),del(11)(q23),
del(20)(q11.2q13.3)[9]
8 RCMD RS
(WHO)
47, XY, + 19
9 RCMD RS
(WHO)
46, XY
10 RAEB1 (WHO) 46, XY
11 RAEB1 (WHO) 46, XY
12 RCMD (WHO) 46, XY
13 RAEB2 (WHO) 43,XY,del(5)(q13q35),add(11)(q23),
-13,psu dic(15;22)(p12;p12),-18[16]
44,idem, + psu dic(15;22)[2]
14 MDS/MPD, NOS
(WHO)
46, XY
15 CMML (WHO) 46, XY, I (17) (q10)
16 RAEB2 (WHO) 46, XY
17 RAEB2 (WHO) 45, XY, -Y
18 CMML-1 46, XY
19 t-MDS 45, XY, t(3;8) (q26.2;q24.1), -7
20 CMML-2 45, X, -Y
MDS myelodysplastic syndromes; NOS not otherwise specified; WHO
World Health Organization; RCMD refractory cytopenia with multi-
lineage dysplasia; RS ringed sideroblasts; RAEB refractory anemia
with excess blasts; MPD myeloproliferative disease; R/O rule out;
CMML chronic myelomonocytic leukemia
Table 3 Correlation analysis of AA mRNA in MDS patients
AA mRNA
Coefficient P value
Blast.count −0.15 0.50
Blast.viability 0.21 0.38
Cytogenetics 0.18 0.45
IPSS 0.16 0.51
Total.cell.viability −0.23 0.36
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occur at the molecular level in MDS. Among the 20 MDS
patients that we assessed, either the whole chromosome 20
or the locus where the AA gene is located (20q13.2) was
deleted in two. However, the AA mRNA levels were
paradoxically higher in these two patients than were levels
in the controls. It seems likely that genetic events that
cannot be detected by conventional cytogenetic methods
led to AA overexpression in these two patients, although
abnormalities at the transcriptional and translational levels
also may occur.
Our finding that AA mRNA levels in AML patients are
significantly higher than in the controls agrees with those of
other studies [11, 12]; however, AA mRNA levels in AML
patients were not significantly different from those in MDS
patients. The up-regulation of AA in both AML and
MDS patients suggests the importance of AA in the
pathogenesis of myeloid neoplasms and as a potential
target for drug development. Some AA inhibitors have
demonstrated promising antiproliferative activity in in
vitro studies and are being explored as potential
anticancer agents in clinical trials [12].
One possible limitation of our study was the unbalanced
male-to-female ratio in both the AML and MDS groups
(men to women, 8:1 in the AML group and 18:2 in the
MDS group). It is known that both sexes have similar
incidences of AML and MDS. The uneven sex ratios were
not caused by selection bias because our patient selection
was based on whether patients had received previous
therapy.
In summary, we found increased AA expression in
CD34
+ cells derived from both AML and MDS patients,
with AA mRNA levels correlating to protein levels but not
to clinicopathologic or cytogenetic findings.
Acknowledgments Parts of this work were presented at the US and
Canadian Academy of Pathology 97th Annual Meeting, Denver, CO,
USA, March 1–7, 2008. Dr. Dongjiu Ye is the recipient of the
Research Fellowship awarded by the Division of Pathology and
Laboratory Medicine, The University of Texas, M. D. Anderson
Cancer Center. We thank Kathryn Hale for her assistance in editing
this manuscript and LaKisha Rodgers for her assistance in formatting
the figures and the manuscript.
Conflict of interest statement The authors declare that they have no
conflict of interest.
References
1. Adams RR, Carmena M, Earnshaw WC (2001) Chromosomal
passengers and the (aurora) ABCs of mitosis. Trends Cell Biol
11:49–54
2. Marumoto T, Zhang D, Saya H (2005) Aurora-A—a guardian of
poles. Nat Rev Cancer 5:42–50
3. Andrews PD (2005) Aurora kinases: shining lights on the
therapeutic horizon? Oncogene 24:5005–5015
4. Li X, Sakashita G, Matsuzaki H et al (2004) Direct association with
innercentromereprotein(INCENP)activatesthenovelchromosomal
passenger protein, aurora-C. J Biol Chem 279:47201–47211
5. Fraizer GC, Diaz MF, Lee IL et al (2004) Aurora-A/STK15/
BTAK enhances chromosomal instability in bladder cancer cells.
Int J Oncol 25:1631–1639
6. Gritsko TM, Coppola D, Paciga JE et al (2003) Activation and
overexpression of centrosome kinase BTAK/aurora-A in human
ovarian cancer. Clin Cancer Res 9:1420–1426
7. Sakakura C, Hagiwara A, Yasuoka R et al (2001) Tumour-amplified
kinase BTAK is amplified and overexpressed in gastric cancers with
possible involvement in aneuploid formation. Br J Cancer 84:824–831
8. Tanaka T, Kimura M, Matsunaga K et al (1999) Centrosomal
kinase AIK1 is overexpressed in invasive ductal carcinoma of the
breast. Cancer Res 59:2041–2044
9. Chieffi P, Cozzolino L, Kisslinger A et al (2006) Aurora B
expression directly correlates with prostate cancer malignancy
and influence prostate cell proliferation. Prostate 66:326–333
10. Yang J, Yang J, Ikezoe T et al (2007) AZD1152, a novel and
selective aurora B kinase inhibitor, induces growth arrest,
apoptosis, and sensitization for tubulin depolymerizing agent
or topoisomerase II inhibitor in human acute leukemia cells in
vitro and in vivo. Blood 110:2034–2040
11. Ikezoe T, Yang J, Nishioka C et al (2007) A novel treatment
strategy targeting aurora kinases in acute myelogenous leukemia.
Mol Cancer Ther 6:1851–1857
12. Huang X-F, Luo S-K, Xu J et al (2008) Aurora kinase inhibitory
VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in
aurora-A-high acute myeloid leukemia. Blood 111:2854–2865
13. Brunning RD, Head D, Bennett JM et al (2001) Myelodysplastic
syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds)
WHO Classification: tumours of haematopoietic and lymphoid
tissues. IARC, Lyon, France, pp 63–76
14. Sun X, Medeiros LJ, Lu D et al (2003) Dysplasia and high
proliferation rate are common in acute myeloid leukemia with inv
(16) (p13q22). Am J Clin Pathol 120:236–245
15. Greenberg P, Cox C, LeBeau MM et al (1997) International
scoring system for evaluating prognosis in myelodysplastic
syndromes. Blood 89:2079–2088
16. Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med
340:1649–1660
17. Landen CN Jr, Lin YG, Immaneni A (2007) Overexpression of the
centrosomal protein aurora-A kinase is associated with poor prognosis
in epithelial ovarian cancer patients. Clin Cancer Res 13:4098–4104
18. Corey SJ, Minden MD, Barber DL et al (2007) Myelodysplastic
syndromes: the complexity of stem-cell diseases. Nat Rev Cancer
7:118–129
8 J Hematopathol (2009) 2:2–8